Drug profile · INN
idarubicin hydrochloride
IDARUBICIN HYDROCHLORIDE
idarubicin hydrochloride (IDARUBICIN HYDROCHLORIDE) is a dna topoisomerase ii alpha inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — idarubicin hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
idarubicin hydrochloride (IDARUBICIN HYDROCHLORIDE) is a dna topoisomerase ii alpha inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase II alpha inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is idarubicin hydrochloride?
idarubicin hydrochloride (IDARUBICIN HYDROCHLORIDE) is a dna topoisomerase ii alpha inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for idarubicin hydrochloride?
IDARUBICIN HYDROCHLORIDE is a marketed brand name for idarubicin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of idarubicin hydrochloride?
idarubicin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.